中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

79 records (took 0.023 seconds)

    COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION
    51.
    发明申请
    COMPOSITION COMPRISING HMOs FOR PREVENTING OR REDUCING NOCICEPTION 有权

    公开(公告)号：US20220233562A1

    公开(公告)日：2022-07-28

    申请号：US17723135

    申请日：2022-04-18

    Applicant: Glycom A/S

    Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Sami Damak ,  Norbert Sprenger ,  Francis Foata

    IPC: A61K31/702 ,  A61P1/00 ,  A61K31/7016

    Abstract: A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6′-sialyllactose (6′-SL), and a mixture of 6′-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6′-SL and LNT that provides a synergistic effect relative to each of the 6′-SL and LNT alone.

    SYNTHETIC COMPOSITION
    52.
    发明申请
    SYNTHETIC COMPOSITION 有权

    公开(公告)号：US20220133759A1

    公开(公告)日：2022-05-05

    申请号：US17577252

    申请日：2022-01-17

    Applicant: Glycom A/S

    Inventor： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Emma Elison

    IPC: A61K31/702 ,  A61P25/00 ,  A61P1/00

    Abstract: A method of increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract and regulating levels of one or both of tryptophan and serotonin in a non-infant human is disclosed. In some examples, the method is effective for treating migraines. The method includes administering for an initial treatment period an amount of one or more human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), difucosyllactose (DFL), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), where the amount is effective to increase the relative abundance of Bifidobacterium adolescentis in the gastrointestinal tract of the non-infant human.

Patent Agency Ranking